

Prof. HALİT SİNAN SÜZEN

Personal Information

Office Phone: [+90 312 203 3000](tel:+903122033000)

Email: suzen@ankara.edu.tr

Web: <https://avesis.ankara.edu.tr/suzen>

Address: Ankara Üniversitesi, Adli Bilimler Enstitüsü, Dikimevi Tıp Fakültesi Kampüsü, Mamak

International Researcher IDs

ORCID: 0000-0003-1779-5850

ScopusID: 7004258890

Yoksis Researcher ID: 169896

Education Information

Doctorate, University of Wales, Swansea, Molecular Genetic And Toxicology, United Kingdom 1992 - 1996

Postgraduate, Ankara University, Sağlık Bilimleri Enstitüsü, Farmasötik Toksikoloji (YI) (Tezli), Turkey 1985 - 1988

Undergraduate, Ankara University, Eczacılık Fakültesi, Eczacılık Pr., Turkey 1981 - 1985

Foreign Languages

English, B2 Upper Intermediate

Dissertations

Doctorate, The Application of Genotypic Analysis to the Study of Environmental Toxicology, University of Wales, Swansea, Molecular Genetic And Toxicology, 1996

Postgraduate, Testosteron ve Metaboliti Epitestosteronun Gaz Kromatograf ile Tayini, Ankara University, Sağlık Bilimleri Enstitüsü, Farmasötik Toksikoloji (YI) (Tezli), 1988

Research Areas

Health Sciences

Academic Titles / Tasks

Professor, Ankara University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, 1985 - Continues

Academic and Administrative Experience

Head of Department, Ankara University, Adli Bilimler Enstitüsü, Adli Toksikoloji Anabilim Dalı, 2016 - 2022

Courses

Farmasötik Toksikoloji, Undergraduate, 2021 - 2022

Advising Theses

SÜZEN H. S., Şizofreni Hastalarında Klozapin ve Norklozapin Kan Plazma Düzeylerine ABCB1 3435C>T ve UGT1A4 L48V Polimorfizmlerinin Etkisi, Doctorate, F.ÖZDEMİR(Student), 2020

SÜZEN H. S., GST omega 1 ve omega 2 gen polimorfizmlerinin talasemi hastalarındaki kan metal düzeylerine etkisi, Doctorate, B.AHSEN(Student), 2019

SÜZEN H. S., Takrolimus kullanan böbrek nakil hastalarında farmakogenetiğin öneminin araştırılması, Doctorate, M.DEMİRBÜGEN(Student), 2019

SÜZEN H. S., Sitokrom P450 2D6 geni RS3892097 polimorfizmi için genotipik analiz yöntemi geliştirilmesi, Postgraduate, G.REJIEPU(Student), 2019

SÜZEN H. S., Modifiye gaz kromatografisi-Headspace yöntemi ile insan plazmasında toluen, benzen, ksilen ve stirenin tayin yönteminin geliştirilmesi ve validasyonu, Postgraduate, A.GÜVEN(Student), 2019

SÜZEN H. S., Arseniğe maruz işçilerde, oksidatif stres ilişkili genlerdeki polimorfizmlerin (MnSOD ve p22phox) ve kan arsenik düzeylerinin, DNA hasarına etkisi, Doctorate, E.BALCIOĞLU(Student), 2019

SÜZEN H. S., Aspirin kullanırken aterotrombotik olay geçiren hastalarda genetik polimorfizmin rolünün araştırılması, Doctorate, B.DEMİREL(Student), 2018

Jury Memberships

Doctorate, Doctorate, Hacettepe Üniversitesi, June, 2022

Doctorate, Doctorate, Ankara Üniversitesi, April, 2022

Doctorate, Doctorate, Ankara Üniversitesi, April, 2022

Doctorate, Doctorate, Ankara Üniversitesi, February, 2022

Doctorate, Doctorate, Ankara Üniversitesi, January, 2022

Post Graduate, Post Graduate, Ankara Üniversitesi, August, 2021

Post Graduate, Post Graduate, Ankara Üniversitesi, September, 2020

Doctorate, Doctorate, Ankara Üniversitesi, February, 2020

Post Graduate, Post Graduate, Ankara Üniversitesi, January, 2020

Doctorate, Doctorate, Ankara Üniversitesi, January, 2020

Post Graduate, Post Graduate, Ankara Üniversitesi, October, 2019

Post Graduate, Post Graduate, Ankara Üniversitesi, August, 2019

Post Graduate, Post Graduate, Ankara Üniversitesi, June, 2019

Post Graduate, Post Graduate, Ankara Üniversitesi, May, 2019

Post Graduate, Post Graduate, Ankara Üniversitesi, August, 2015

Doctorate, Doctorate, Ankara Üniversitesi, January, 2015

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The role of tissue persistent organic pollutants and genetic polymorphisms in patients with benign and malignant kidney tumors**
KOCAGÖZ R., Onat I., Oz M. D., Turna B., Kumbaraci B. S., ORMAN M. N., SÜZEN H. S., ORHAN H.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, vol.110, 2024 (SCI-Expanded)
- II. **Blood and tissue levels of persistent organic pollutants and genetic susceptibility in patients with breast cancer**

Onat İ., Kocagöz R., DEMİR BÜĞEN ÖZ M., Yeniay L., Tiftikçioğlu Y. Ö., Zekioğlu O., Serin G., Özdemir M., Gür E., SÜZEN H. S., et al.

Environmental Toxicology and Pharmacology, vol.108, 2024 (SCI-Expanded)

- III. **The relationship between lymphocyte DNA damage, coronary artery disease, and blood trace elements**
Erdogu I., DURAL E., ALTUNDAĞ H., OYMAK T., SÜZEN H. S.
MUTAGENESIS, no.1, pp.43-55, 2024 (SCI-Expanded)
- IV. **Evaluation of distal tibial epiphysis and calcaneal epiphysis according to the Vieth method in 3.0 T magnetic resonance images: a pilot study**
Gurses M. S., Has B., Altinsoy H. B., SÜZEN H. S.
INTERNATIONAL JOURNAL OF LEGAL MEDICINE, vol.137, no.4, pp.1181-1191, 2023 (SCI-Expanded)
- V. **Association between superoxide dismutase 2, glutathione peroxidase 1, xeroderma pigmentosum group d gene variations, and head and neck squamous cell cancer susceptibility**
Kose G., Oz M., CÖMERT E., SÜZEN H. S.
ARCHIVES OF BIOLOGICAL SCIENCES, vol.74, no.2, pp.181-189, 2022 (SCI-Expanded)
- VI. **Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.**
Eap C. B., Grunder G., Baumann P., Ansermot N., Conca A., Corruble E., Crettol S., Dahl M. L., de Leon J., Greiner C., et al.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, vol.22, no.8, pp.561-628, 2021 (SCI-Expanded)
- VII. **The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants**
DEMİR BÜĞEN ÖZ M., Ozdemir F., SÜZEN H. S.
Current drug metabolism, vol.22, no.8, pp.596-627, 2021 (SCI-Expanded)
- VIII. **The Effect of Enantiomer Elution Order on the Determination of Minor Enantiomeric Impurity in Ketoprofen and Enantiomeric Purity Evaluation of Commercially Available Dexketoprofen Formulations**
Tok K. C., Gümüştas M., Jibuti G., Süzen H. S., Özkan S. A., Chankvetadze B.
MOLECULES, vol.25, no.24, 2020 (SCI-Expanded)
- IX. **The role of COMT polymorphism in modulation of prefrontal activity during verbal fluency in bipolar disorder**
Devrimci-Ozguven H., Alici Y. H., DEMİR BÜĞEN ÖZ M., SÜZEN H. S., Kale H. E., Baskak B.
NEUROSCIENCE LETTERS, vol.738, 2020 (SCI-Expanded)
- X. **The relationship between plasma levels of clozapine and N-desmethyclozapine as well as M1 receptor polymorphism with cognitive functioning and associated cortical activity in schizophrenia**
Kir Y., BASKAK B., Kusman A., Sayar-Akaslan D., Ozdemir F., Sedes-Baskak N., SÜZEN H. S., BARAN Z.
PSYCHIATRY RESEARCH-NEUROIMAGING, vol.303, 2020 (SCI-Expanded)
- XI. **Association between serotonin 2A receptor (HTR2A), serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients**
DEMİR BÜĞEN ÖZ M., BASKAK B., UÇKUN Z., Artun N. Y., Ozdemir H., Ozel T. K., ÖZGÜVEN H., SÜZEN H. S.
PHARMACOGENOMICS JOURNAL, vol.20, no.3, pp.443-450, 2020 (SCI-Expanded)
- XII. **Determination of Mirtazapine and Desmethyl Mirtazapine in Human Plasma by a New Validated HPLC Ultraviolet Method with a Simple and Reliable Extraction Method: Application to Therapeutic Drug Monitoring Study by 62 Real Patient Plasma**
DURAL E., Baskak N. S., Ozcan H., Kir Y., BASKAK B., SÜZEN H. S.
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, vol.19, no.1, pp.18-30, 2020 (SCI-Expanded)
- XIII. **A Novel PCR-RFLP Method for Detection of POR*28 Polymorphism and its Genotype/Allele Frequencies in a Turkish Population**
Ozdemir F., DEMİR BÜĞEN ÖZ M., SÜZEN H. S.

CURRENT DRUG METABOLISM, vol.20, no.10, pp.845-851, 2019 (SCI-Expanded)

- XIV. **The relationship between the serotonin 2A receptor gene-1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients**
DEMİR BÜĞEN ÖZ M., UÇKUN Z., YUCE-ARTUN N., BASKAK B., ÖZDEMİR H., ÖZEL T. K., ÖZGÜVEN H., SÜZEN H. S.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, vol.33, no.5, 2018 (SCI-Expanded)
- XV. **Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients**
YUCE-ARTUN N., BASKAK B., ÖZEL KIZIL E. T., ÖZDEMİR H., UÇKUN Z., ÖZGÜVEN H., SÜZEN H. S.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, vol.38, no.2, pp.388-394, 2016 (SCI-Expanded)
- XVI. **Association Between the 5 HTTLPR Polymorphism and Response to Citalopram in Turkish Patients with Major Depressive Disorder**
UÇKUN Z., BASKAK B., ÖZDEMİR REZAKİ H., ÖZEL KIZIL E. T., ÖZGÜVEN H., SÜZEN H. S.
Turkish Journal Of Biology, vol.13, no.2, pp.145-158, 2016 (SCI-Expanded)
- XVII. **The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder**
Uçkun Z., Baskak B., ÖZEL KIZIL E. T., ÖZDEMİR H., ÖZGÜVEN H., SÜZEN H. S.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, vol.40, no.6, pp.672-679, 2015 (SCI-Expanded)
- XVIII. **DETERMINATION OF SERTRALINE AND ITS METABOLITE BY HIGH-PRESSURE LIQUID CHROMATOGRAPHY IN PLASMA**
YUCE-ARTUN N., ÖZEL KIZIL E. T., BASKAK B., ÖZGÜVEN H., DUYDU Y., SÜZEN H. S.
REVUE ROUMAINE DE CHIMIE, vol.60, no.5-6, pp.543-548, 2015 (SCI-Expanded)
- XIX. **Allele and genotype frequencies of CYP2B6 in a Turkish population**
YUCE-ARTUN N., KOSE G., SÜZEN H. S.
MOLECULAR BIOLOGY REPORTS, vol.41, no.6, pp.3891-3896, 2014 (SCI-Expanded)
- XX. **Evaluation of the genotoxic effects of patients undergoing hyperbaric oxygen (HBO) therapy**
Hiperbarik oksijen tedavisinin (HBOT) sebep olduğu genotoksik etkilerin İncelenmesi
ÜSTÜNDAĞ A., ŞİMŞEK K., AY H., DÜNDAR K., SÜZEN H. S., AYDIN A., DUYDU Y.
Turkish Journal of Pharmaceutical Sciences, vol.11, no.2, pp.203-208, 2014 (SCI-Expanded)
- XXI. **CYTOGENETIC DAMAGE IN TURKISH COKE OVEN WORKERS EXPOSED TO POLYCYCLIC AROMATIC HYDROCARBONS: ASSOCIATION WITH CYP1A1, CYP1B1, EPHX1, GSTM1, GSTT1, AND GSTP1 GENE POLYMORPHISMS**
ADA A. O., DEMİROĞLU C., YILMAZER M., SÜZEN H. S., DEMİRBAĞ A. E., EFE S., ALEMDAR Y., İSCAN M., BURGAZ S.
ARHIV ZA Higijenu Rada I Toksikologiju-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, vol.64, no.3, pp.359-369, 2013 (SCI-Expanded)
- XXII. **DNA integrity in patients undergoing hyperbaric oxygen (HBO) therapy**
ÜSTÜNDAĞ A., ŞİMŞEK K., AY H., DÜNDAR K., SÜZEN H. S., AYDIN A., DUYDU Y.
TOXICOLOGY IN VITRO, vol.26, no.7, pp.1209-1215, 2012 (SCI-Expanded)
- XXIII. **The relationship of PON1 QR 192 and LM 55 polymorphisms with serum paraoxonase activities of Turkish diabetic patients**
ALTUNER D., ATEŞ İ., SÜZEN H. S., KOC G. V., ARAL Y., KARAKAYA A.
TOXICOLOGY AND INDUSTRIAL HEALTH, vol.27, no.10, pp.873-878, 2011 (SCI-Expanded)
- XXIV. **Are PON1 Q/R 192 and M/L 55 polymorphisms risk factors for diabetes complications in Turkish population?**
ALTUNER D., SÜZEN H. S., ATEŞ İ., KOC G. V., ARAL Y., KARAKAYA A.
CLINICAL BIOCHEMISTRY, vol.44, no.5-6, pp.372-376, 2011 (SCI-Expanded)
- XXV. **Possible effect of gene polymorphisms on the release of TNF alpha and IL1 cytokines in coal workers' pneumoconiosis**
ATEŞ İ., YUCESOY B., ATAĞ YÜCEL A., SÜZEN H. S., KARAKAS Y., KARAKAYA A.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, vol.63, no.1-2, pp.175-179, 2011 (SCI-Expanded)
- XXVI. **CAT C-262T and GPX1 Pro198Leu polymorphisms in a Turkish population**
SÜZEN H. S., GUCYENER E., SAKALLI O., UÇKUN Z., KOSE G., USTEL D., DUYDU Y.

- MOLECULAR BIOLOGY REPORTS, vol.37, no.1, pp.87-92, 2010 (SCI-Expanded)
- XXVII. **CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients**
Ada A. O., Kunak S. C., Hancer F., Bilgen S., SÜZEN H. S., Alpar S., Gulhan M., Kurt B., Iscan M.
NEOPLASMA, vol.57, no.6, pp.512-521, 2010 (SCI-Expanded)
- XXVIII. **Association of cytokine gene polymorphisms in CWP and its severity in Turkish coal workers**
Ates İ., SÜZEN H. S., Yucesoy B., TEKİN İ. Ö., Karakaya A.
AMERICAN JOURNAL OF INDUSTRIAL MEDICINE, vol.51, no.10, pp.741-747, 2008 (SCI-Expanded)
- XXIX. **The role of GSTM1 and GSTT1 polymorphisms in head and neck cancer risk**
SÜZEN H. S., Guvenc G., Turanli M., Comert E., Duydu Y., ELHAN A. H.
ONCOLOGY RESEARCH, vol.16, no.9, pp.423-429, 2007 (SCI-Expanded)
- XXX. **Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett's oesophagus**
Jenkins G. J. S., D'Souza F. R., SÜZEN H. S., Eltahir Z. S., James S. A., Parry J. M., Griffiths P. A., Baxter J. N.
CARCINOGENESIS, vol.28, no.1, pp.136-142, 2007 (SCI-Expanded)
- XXXI. **Polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1 in a male Turkish population**
Ada A. O., SÜZEN H. S., Iscan M.
INTERNATIONAL JOURNAL OF TOXICOLOGY, vol.26, no.1, pp.41-46, 2007 (SCI-Expanded)
- XXXII. **Cytokine genes in susceptibility to coal workers' pneumoconiosis**
Karakaya A., Ates İ., Yucesoy B., SÜZEN H. S.
TOXICOLOGY LETTERS, vol.164, 2006 (SCI-Expanded)
- XXXIII. **Biological monitoring of environmental exposure to polycyclic aromatic hydrocarbons: 1-hydroxypyrene in urine of Turkish coke oven workers**
Yilmazer M., Ada A., SÜZEN H. S., Demiroglu C., Demiroglu A., Efe S., Alemdar Y., Iscan M., Burgaz S.
BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, vol.76, no.4, pp.559-565, 2006 (SCI-Expanded)
- XXXIV. **TYMS and DPYD polymorphisms in a Turkish population**
SÜZEN H. S., Yuce N., Guvenc G., Duydu Y., Erke T.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.61, no.12, pp.881-885, 2005 (SCI-Expanded)
- XXXV. **Evaluation of increased proportion of cells with unusually high sister chromatid exchange counts as a cytogenetic biomarker for lead exposure**
Duydu Y., Dur A., SÜZEN H. S.
BIOLOGICAL TRACE ELEMENT RESEARCH, vol.104, no.2, pp.121-129, 2005 (SCI-Expanded)
- XXXVI. **Molecular analysis of delta-aminolevulinic acid dehydratase (ALAD) gene polymorphism in a Turkish population**
SÜZEN H. S., Duydu Y., Aydin A.
BIOCHEMICAL GENETICS, vol.42, no.11-12, pp.461-467, 2004 (SCI-Expanded)
- XXXVII. **The oxidative DNA base damage in testes of rats after intraperitoneal cadmium injection**
Ates İ., SÜZEN H. S., Aydin A., Karakaya A.
BIOMETALS, vol.17, no.4, pp.371-377, 2004 (SCI-Expanded)
- XXXVIII. **Polymorphisms of cytochrome P450 1A1, glutathione S-transferases M1 and T1 in a Turkish population**
Ada A., SÜZEN H. S., Iscan M.
TOXICOLOGY LETTERS, vol.151, no.1, pp.311-315, 2004 (SCI-Expanded)
- XXXIX. **Influence of delta-aminolevulinic acid dehydratase (ALAD) polymorphism on the frequency of sister chromatid exchange (SCE) and the number of high-frequency cells (HFCs) in lymphocytes from lead-exposed workers**
Duydu Y., SÜZEN H. S.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, vol.540, no.1, pp.79-88, 2003 (SCI-Expanded)
- XL. **Influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism on biomarkers of lead**

- exposure in Turkish storage battery manufacturing workers**
SÜZEN H. S., Duydu Y., Aydin A., Isimer A., Vural N.
AMERICAN JOURNAL OF INDUSTRIAL MEDICINE, vol.43, no.2, pp.165-171, 2003 (SCI-Expanded)
- XLII. **Correlation between lead exposure indicators and sister chromatid exchange (SCE) frequencies in lymphocytes from inorganic lead exposed workers**
Duydu Y., SÜZEN H. S., Aydin A., Cander O., Uysal H., Isimer A., Vural N.
ARCHIVES OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, vol.41, no.2, pp.241-246, 2001 (SCI-Expanded)
- XLIII. **The oxidative DNA base damage in testes tissue of rats after intraperitoneal cadmium injection**
Karakaya A., Ates İ., Jaruga P., SÜZEN H. S., Dizdaroglu M.
TOXICOLOGY, vol.164, no.1-3, pp.58-59, 2001 (SCI-Expanded)
- XLIV. **Analysis of ras gene mutation in human oral tumours by polymerase chain reaction and direct sequencing**
SÜZEN H. S., Parry J. M.
Turkish Journal of Medical Sciences, vol.31, no.3, pp.217-223, 2001 (SCI-Expanded)
- XLV. **Simultaneous determination of guaiphenesin and codeine phosphate in tablets by high-performance liquid chromatography**
SÜZEN H. S., Akay C., Cevheroglu S.
FARMACO, vol.54, no.10, pp.705-709, 1999 (SCI-Expanded)
- XLVI. **The restriction site mutation assay: a review of the methodology development and the current status of the technique**
Jenkins G., SÜZEN H. S., Sueiro R., Parry J.
MUTAGENESIS, vol.14, no.5, pp.439-448, 1999 (SCI-Expanded)
- XLVII. **Validation of hippuric acid as a biomarker of toluene exposure**
Duydu Y., SÜZEN H. S., Erdem N., Uysal H., Vural N.
BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, vol.63, no.1, pp.1-8, 1999 (SCI-Expanded)
- XLVIII. **Urinary excretion of total and inorganic lead in tetraethyllead exposed workers**
Duydu Y., SÜZEN H. S., Aydin A., Sayal A., Isimer A., Vural N.
BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, vol.60, no.3, pp.395-401, 1998 (SCI-Expanded)
- XLIX. **Application of the restriction site mutation technique to N-methyl-N-nitrosourea-induced mutations in the rat**
SÜZEN H. S., Jenkins G., Parry J.
TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS, vol.18, no.4, pp.171-182, 1998 (SCI-Expanded)
- L. **EVALUATION OF THE BIOLOGICAL THRESHOLD VALUE OF URINARY CADMIUM CONCENTRATION IN A GROUP OF WORKERS**
KARAKAYA A., SÜZEN H. S., VURAL N., OFLAZ G.
BULLETIN OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY, vol.51, no.4, pp.483-489, 1993 (SCI-Expanded)
- L. **ANALYSIS OF THE SERUM PARAOXONASE ARYLESTERASE POLYMORPHISM IN A TURKISH POPULATION**
KARAKAYA A., SÜZEN H. S., SARDAS S., KARAKAYA A., VURAL N.
PHARMACOGENETICS, vol.1, no.1, pp.58-61, 1991 (SCI-Expanded)

Articles Published in Other Journals

- I. **A Novel Genotyping Method for Detection of the Muscarinic Receptor M1 Gene rs2067477 Polymorphism and Its Genotype/Allele Frequencies in a Turkish Population**
Ozdemir F., Kir Y., TOK K. C., BASKAK B., SÜZEN H. S.
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, vol.17, no.6, pp.653-658, 2020 (ESCI)

- II. **Genotype and Allele Frequency of CYP3A4-392A > G in Turkish Patients with Major Depressive Disorder**
UÇKUN Z., BASKAK B., Ozdemir H., ÖZEL KIZIL E. T., ÖZGÜVEN H., SÜZEN H. S.
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, vol.15, no.2, pp.200-206, 2018 (ESCI)
- III. **Genotype and Allele Frequency of CYP3A4-392A G in Turkish patients with major depressive disorder CYP3A4-392A G and Major Depressive Disorder.**
UÇKUN Z., BASKAK B., ÖZDEMİR REZAKİ H., ÖZEL KIZIL E. T., ÖZGÜVEN H., SÜZEN H. S.
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, vol.15, no.2, pp.200-206, 2018 (Scopus)
- IV. **A Genotyping and Phenotyping Study Concerning the Possible Effects of Some Inflammatory Cytokine Gene Polymorphisms on the Development of Coal Workers' Pneumoconiosis**
ATEŞ İ., KARAKAYA M. A., SÜZEN H. S., YÜCESOY B.
SOJ Immunology, vol.5, no.1, pp.1-5, 2017 (Peer-Reviewed Journal)
- V. **Possible effects of Paraoxonase 1 Q192R polymorphism on serum paraoxonase activities of a group of type 2 Diabetes Mellitus patients.**
ATEŞ İ., ALTUNER D., SÜZEN H. S., Varan Koç G., KARAKAYA M. A.
Open Access Journal of Pharmaceutical Research, vol.1, no.4, pp.1-6, 2017 (Peer-Reviewed Journal)
- VI. **Association between the 5-HTTLPR polymorphism and response to citalopram in Turkish patients with major depressive disorder Major Depresif Bozukluğu Olan Türk Hastalarda 5-HTTLPR Polimorfizminin ve Sitalopram Yanıtı Arasındaki İlişkisi**
Uckun Z., BASKAK B., Ozdemir H., Ozelkizil E. T., Devrimci Ozguven H., SÜZEN H. S.
Turkish Journal of Pharmaceutical Sciences, vol.13, no.2, pp.145-158, 2016 (Scopus)
- VII. **Investigation of the Association between the CYP7A1 A 203C Polymorphism and Barrett's Esophagus in British Population**
UÇKUN Z., McADAM L., SÜZEN H. S., JENKINS G.
JOURNAL OF APPLIED BIOLOGICAL SCIENCES, vol.9, no.1, pp.69-71, 2015 (Peer-Reviewed Journal)
- VIII. **Evaluation of the Genotoxic Effects of Patients Undergoing Hyperbaric Oxygen (HBO) Therapy**
ÜSTÜNDAĞ A., ŞİMŞEK K., AY H., DüNDAR K., SÜZEN H. S., AYDIN A., DUYDU Y.
TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, vol.11, no.2, pp.203-208, 2014 (Scopus)
- IX. **Cytogenetic Damage in Turkish Coke Oven Workers Exposed to Polycyclic Aromatic Hydrocarbons: Association with CYP1A1, CYP1B1, EPHX1, GSTM1, GSTT1, and GSTP1 Gene Polymorphisms**
ADA A. O., demiroğlu c., yilmazer m., SÜZEN H. S., Demirbağ A., Efe S., Alemdar Y., İŞCAN M., BURGAZ S.
Arh Hig Rada Toksikol, vol.64, no.3, pp.359-369, 2013 (Peer-Reviewed Journal)
- X. **Quantitative determination of citalopram and its metabolite desmethycitalopram in plasma by high performance liquid chromatography**
Uckun Z., SÜZEN H. S.
Fabad Journal of Pharmaceutical Sciences, vol.34, no.4, pp.195-201, 2009 (Scopus)
- XI. **Delta-aminolevulinic acid dehydratase (ALAD) genetic polymorphism in Turkish population**
SÜZEN H. S.
Ankara Üniversitesi Eczacılık Fakültesi Dergisi, vol.30, no.1, pp.27-38, 2001 (Scopus)
- XII. **Restriction site mutation analysis in tobacco smoke exposed rats Sigara dumanına maruz bırakılmış sicanlarda sinirli bölge mutasyon analizi**
SÜZEN H. S., Parry J.
Acta Pharmaceutica Turcica, vol.41, no.4, pp.165-171, 1999 (Scopus)
- XIII. **A genotypic mutation technique: Restriction site mutation method**
SÜZEN H. S., Parry J.
Ankara Üniversitesi Eczacılık Fakültesi Dergisi, vol.28, no.2, pp.85-97, 1999 (Scopus)
- XIV. **The use of an internal standard molecule for determining mutation frequency in restriction site mutation method**
Süzen H. S., Parry J.
Ankara Üniversitesi Eczacılık Fakültesi Dergisi, vol.28, no.1, pp.1-13, 1999 (Scopus)
- XV. **Analysis of 7,12-dimethylbenz[a]anthracene induced mutations by the use of restriction site**

mutation technique in the rat

SÜZEN H. S., Parry J.

Fabad Journal of Pharmaceutical Sciences, vol.24, no.2, pp.67-73, 1999 (Scopus)

XVI. A modified method for determination of hippuric acid in urine by HPLC

DUYDU Y., SÜZEN H. S., VURAL N., ERDEM N., UYSAL H.

Ankara Üniversitesi Eczacılık Fakültesi Dergisi, vol.28, no.1, pp.37-46, 1999 (Scopus)

Books & Book Chapters

- I. **Major Depresyonda Bireyselleştirilmiş Tedavi ve Farmakogenetiğin Önemi**
DEMİRBÜGEN ÖZ M., SÜZEN H. S.
in: Eczacılıkta Yenilikler 3, Özçelikay Gülbin, Yıldız İlkay, Editor, Ankara Üniversitesi Yayınları, Ankara, pp.447-456, 2020
- II. **Türk Farmakopesi-II Monograflar**
ÖZKAN Y., İŞCAN G. S., SARAÇ TARHAN S., ÖZKAN S. A., AYDIN A., SÜZEN H. S., SÜZEN S., KÜÇÜKGÜZEL İ., YÜKSEL N., ARICA YEGİN B., et al.
Anıl Reklam Matbaa LTD.STİ., 2017
- III. **Casarett And Doull's Toksikolojinin Temelleri**
SÜZEN H. S., ERKEKOĞLU Ü. P., ADA A. O., ERDEM O., ÇAKMAK G., demirel b.
Nobel, Ankara, 2017
- IV. **TÜRK FARMAKOPESİ-II MONOGRAFLAR (Avrupa Farmakopesi Adaptasyonu) - 2016**
ÖZKAN Y., SALTAN H. G., SARAÇ TARHAN S., ÖZKAN S. A., AYDIN A., SÜZEN H. S., KÜÇÜKGÜZEL İ., SÜZEN S., YÜKSEL N., ARICA YEGİN B., et al.
T.C. Sağlık Bakanlığı Türkiye ilaç ve Tıbbi Cihaz. Kurumu, Ankara, 2016
- V. **Türk Farmakopesi II Monograflar Avrupa Farmakopesi Adaptasyonu 2016**
SAVAŞER A., HASÇİÇEK C., ÖZKAN S. A., ÖZKAN Y., besicki a., Tas c., sarac tarhan s., KÖSE ÖZKAN C., ARICA YEGİN B., USLU B., et al.
Anıl Reklam Matbaa ltd., 2016

Refereed Congress / Symposium Publications in Proceedings

- I. **Assessment of Genetic and Lifestyle Factors on Clozapine and N-desmethylclozapine Plasma Levels in Schizophrenia Patients**
Demirbügen Öz M., Özdemir F., Tok K. C., Dural E., Kır Y., Ulusoy M., Gümüştaş M., Baskak B., Süzen H. S.
XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP, Freiburg, Germany, 20 - 22 March 2024, pp.87
- II. **Extraction Strategies for Simultaneous Determination of the Buprenorphine/Naloxone Combination from Plasma Samples**
BOZMAOĞLU C. H., BAŞARIR E. P., TOK K. C., DANIŞMAN M., SÜZEN H. S., GÜMÜŞTAŞ M.
12th Annual Symposium on Physical and Analytical Chemistry (ASPAC 2023), Tbilisi, Georgia, 15 - 17 December 2023
- III. **Sample Preparation and Analysis with the Spotlight on Forensically and Clinically Important Drugs**
GÜMÜŞTAŞ M., BOZMAOĞLU C. H., TOK K. C., SÜZEN H. S.
12th Annual Symposium on Physical and Analytical Chemistry (ASPAC 2023), Tbilisi, Georgia, 15 - 17 December 2023
- IV. **Analytical Method Development and Validation of Pregabalin and Gabapentin in Pharmaceutical, Biological, and Environmental Samples Using HPLC**
TOK K. C., BOZMAOĞLU C. H., SÜZEN H. S., GÜMÜŞTAŞ M.
60th annual meeting of the International Association of Forensic Toxicologists (TIAFT 2023), ROMA, Italy, 27 - 31

August 2023

- V. **Therapeutic Drug Monitoring: A Bioanalytical Method for Naltrexone and Major Metabolite**
GÜMÜŞTAŞ M., BOZMAOĞLU C. H., TOK K. C., SÜZEN H. S., DANIŞMAN M.
60th annual meeting of the International Association of Forensic Toxicologists (TIAFT 2023), ROMA, Italy, 27 - 31 August 2023
- VI. **Evaluation of Dilute-and-Shoot and Liquid-Phase Extraction Methods for the Analysis of Buprenorphine/Naloxone Combination Used in the Treatment of Opioid Addiction**
BOZMAOĞLU C. H., BAŞARIR E. P., TOK K. C., SÜZEN H. S., GÜMÜŞTAŞ M.
60th annual meeting of the International Association of Forensic Toxicologists (TIAFT 2023), ROMA, Italy, 27 - 31 August 2023
- VII. **LC-MS/MS-Based Quantitative Analysis of A Tricyclic Antidepressant and Its Major Metabolite**
BOZKURT N. N., TOK K. C., BOZMAOĞLU C. H., YALÇINKAYA B., BASKAK B., GÜMÜŞTAŞ M., SÜZEN H. S.
33rd International Symposium on Pharmaceutical and Biomedical Analysis (PBA2023), Ankara, Turkey, 02 July 2023
- VIII. **Accurate and Precise Determination of Pregabalin in Pharmaceutical Formulations using HPLC-UV Methodology**
TOK K. C., BOZMAOĞLU C. H., SÜZEN H. S., GÜMÜŞTAŞ M.
33rd International Symposium on Pharmaceutical and Biomedical Analysis (PBA2023), Ankara, Turkey, 02 July 2023
- IX. **The Effect of Pharmacokinetic Genes Polymorphisms to the Plasma Clozapine and Norclozapine Levels in Patients with Schizophrenia**
ÖZDEMİR F., TOK K. C., DURAL E., GÜMÜŞTAŞ M., BASKAK B., SÜZEN H. S.
33rd International Symposium on Pharmaceutical and Biomedical Analysis (PBA2023), Ankara, Turkey, 02 July 2023
- X. **New Perspectives for the Extraction of Naltrexone and its Metabolite Used in the Treatment of Opioid Use Disorder**
Bozmaoğlu H. C., Tok K. C., Gümüştas M., Süzen H. S.
2nd European Sample Preparation e-Conference (EuSP2022), 14 - 16 March 2022, pp.1
- XI. **THE IMPACT OF THE CYTOCHROME P450 3A4 (CYP3A4*22) POLYMORPHISM ON TACROLIMUS DOSE REQUIREMENTS AND EXPOSURE DURING EARLY PERIOD FOLLOWING KIDNEY TRANSPLANTATION**
DEMİRBUĞEN ÖZ M., KEVEN K., SÜZEN H. S.
13th International Symposium on Pharmaceutical Sciences (ISOPS), Ankara, Turkey, 22 - 25 June 2021
- XII. **Development of HPLC Method for the Determination of Opioid Antagonist Used in the Treatment of Opioid Disorder**
BOZMAOĞLU C. H., TOK K. C., TEKTAŞ S., SERİM T. M., YÜKSEL N., ÖZDEMİR A. N., SÜZEN H. S., GÜMÜŞTAŞ M.
3rd International Gazi Pharma Symposium Series (GPSS2021), Turkey, 08 September 2021
- XIII. **THE IMPORTANCE OF THE CYTOCHROME P450 3A5 (CYP3A5*3) POLYMORPHISM ON TACROLIMUS DOSE REQUIREMENTS AND TROUGH LEVELS DURING EARLY PERIOD AFTER KIDNEY TRANSPLANTATION**
DEMİRBUĞEN ÖZ M., KEVEN K., SÜZEN H. S.
2nd INTERNATIONAL CONGRESS OF MULTIDISCIPLINARY STUDIES IN MEDICAL SCIENCES, Ankara, Turkey, 13 - 14 February 2021
- XIV. **The Effect of Enantiomer Elution Order on Determination of Minor Enantiomeric Impurity: The Case of Ketoprofen**
TOK K. C., GÜMÜŞTAŞ M., SÜZEN H. S., ÖZKAN S. A., FARKAS T., CHANKVETADZE B.
2nd International Congress on Analytical and Bioanalytical Chemistry (2nd ICABC 2020) Antalya/Türkiye, Antalya, Turkey, 11 - 14 March 2020
- XV. **Adli veteriner toksikoloji yönüyle hayvan istismarı**
YURDAKÖK DİKMEN B., SÜZEN H. S.
I. International VI. Veterinary Pharmacology and Toxicology Congress., Kayseri, Turkey, 4 - 07 September 2019, pp.254-264

- XVI. **Efficient Extraction Method for Simultaneous Determination of Bisphenols and Phthalates in Meconium Specimens Using GC-MS**
Tok K. C., Gümüştaş M., Mohamed K. M., Arsan S., Gürbüz A., Süzen H. S.
EUROANALYSIS XX, İstanbul, Turkey, 1 - 05 September 2019, pp.1
- XVII. **The role of genetic and epigenetic factors in major depressive disorder**
DEMİR BÜĞEN ÖZ M., SÜZEN H. S.
5th International Congress on Epigenetics Chromatin, Viyana, Austria, 22 - 23 August 2019
- XVIII. **Relationship of clozapine plasma level, 5-HT2A rs6311 and rs6313 polymorphisms with obsessive-compulsive symptoms in schizophrenia patients under clozapine monotherapy**
KIR Y., BASKAK B., KUŞMAN A., SAYAR AKASLAN D., SEDES BASKAK N., BARAN Z., SÜZEN H. S.
11th International Congress on Psychopharmacology, Antalya, Turkey, 18 - 21 April 2019, vol.29, pp.100-101
- XIX. **Rapid Determination of Clozapine and Main Metabolite by High Performance Liquid Chromatography**
TOK K. C., ÖZDEMİR F., GÜMÜŞTAŞ M., SÜZEN H. S.
1st INTERNATIONAL CONGRESS on ANALYTICAL and BIOANALYTICAL CHEMISTRY, Antalya, Turkey, 27 - 30 March 2019
- XX. **The Role of Comt Polymorphisms in Modulation of Prefrontal Activity During Verbal Fluency in Bipolar Disorder**
HOŞGÖREN Y., DEVRİMCİ ÖZGÜVEN H., BASKAK B., DEMİR BÜĞEN ÖZ M., SÜZEN H. S., DUMAN B.
Bipolar Bozukluklar Derneği Bipolar Bozukluk Araştırmacı Klinisyen Eğitim Toplantısı (BAKET), Turkey, 15 - 16 September 2018
- XXI. **THE POSSIBLE ASSOCIATION BETWEEN BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) GENETIC POLYMORPHISM VAL66MET AND SUSCEPTIBILITY TO BIPOLAR DISORDERS (BPD)**
DEMİR BÜĞEN ÖZ M., HOŞGÖREN Y., DUMAN B., BASKAK B., DEVRİMCİ ÖZGÜVEN H., SÜZEN H. S.
12th International Symposium on Pharmaceutical Sciences (ISOPS-12), 26 - 29 June 2018
- XXII. **THE 5-HYDROXYTRİPTAMİNE 2A RECEPTOR -1438A/G AND 102T/C POLİMORPHİSMS AND NAUSEA SIDE EFFECT IN CİTALOPRAM TREATED MAJOR DEPRESSİVE DISORDER PATİENTS**
DEMİR BÜĞEN ÖZ M., UÇKUN Z., YÜCE ARTUN N., DEVRİMCİ ÖZGÜVEN H., SÜZEN H. S.
12th International Symposium on Pharmaceutical Sciences, 26 - 29 June 2018
- XXIII. **COMMON GENE POLYMORPHISMS IN ANTİOXİDANT ENZYME SYSTEMS AND İTS RELATION WITH THE NUTRİON**
DEMİR BÜĞEN M., SÜZEN H. S.
1st International Food and Medicine Congress, 24 - 27 May 2018
- XXIV. **THE RELATIONSHIP BETWEEN THE DIFFERENT GENETIC POLYMORPHISMS AND METHYLPHENİDATE İNDUCED ADVERSE DRUG REACTIONS IN ATTENTION DEFİCİT HYPERACTİVİTY DISORDER PATİENTS**
DEMİR BÜĞEN M., SÜZEN H. S.
1st International Food and Medicine Congress, 24 - 27 May 2018
- XXV. **Kidney, breast and stomach cancers in relation to internal concentrations of persistent organic pollutants, DNA damage markers and related polymorphisms**
ORHAN H., SÜZEN H. S., KOCAGÖZ R., ONAT İ., DEMİR BÜĞEN ÖZ M., TURNA B., ATILA K., YENİAY L., SARIK KUMBARACI B., ZEKİOĞLU O., et al.
The 10th Congress of the Toxicology in Developing Countries (CTDC10th), 17 - 22 April 2018, vol.4, pp.18
- XXVI. **Quantitative Determination of Mirtazapine and Its Major Metabolite in Plasma by a Developed and Validated HPLC-UV Method**
DURAL E., ÖZCAN H., SÜZEN H. S.
1st International Symposium on Multidisciplinary Studies and Innovative Technologies, Tokat, Turkey, 2 - 04 November 2017
- XXVII. **The effects of some cytokine gene polymorphisms on type 2 diabetes and its complications.**
ATEŞ İ., ALTUNER D., SÜZEN H. S., KARAKAYA M. A.
2nd International Gazi Pharma Symposium Series, 11 - 13 October 2017
- XXVIII. **The Serotonin 2A Receptor Gene -1438A/G Polymorphism and Sertraline Induced Nausea in Major Depressed Turkish Patients**

DEMİR BÜĞEN M., UÇKUN Z., SÜZEN H. S.

2nd International Gazi Pharma Symposium Series (GPSS-2017), Ankara, Turkey, 11 - 13 October 2017

- XXIX. **DETERMINATION OF MIRTAZAPINE AND DESMETHYL MIRTAZAPINE IN PLASMA BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ULTRAVIOLET DETECTION**
DURAL E., ÖZCAN H., SÜZEN H. S.
2nd International Gazi Pharma Symposium Series (GPSS-2017), 11 - 13 October 2017
- XXX. **Plazma Sitalopram ve Metaboliti Desmetilsitalopramın Major Depresif Hastalarda HPLC ile Tayini**
SÜZEN H. S., UÇKUN Z., ÖZGÜVEN H.
17. Kromatografi Kongresi, Turkey, 20 - 22 September 2017
- XXXI. **Plazma sitalopram ve metaboliti desmetilsitalopramın majör depresif hastalarda HPLC ile tayini**
SÜZEN H. S., UÇKUN Z., ÖZGÜVEN H.
17. Kromatografi Kongresi, Çorum, Turkey, 20 - 22 September 2017
- XXXII. **Sitalopram kullanan major depresyon hastalarında bulantı/kusma advers etkisinin serotonin-2A reseptör geni -1438A/G polimorfizmi ile ilişkisinin incelenmesi**
DEMİR BÜĞEN M., SÜZEN H. S.
1. Anadolu Üniversitesi Eczacılık Fakültesi Sempozyumu, Turkey, 1 - 02 June 2017
- XXXIII. **The role of some cytokine gene polymorphisms on Type 2 diabetes**
ATEŞ İ., SÜZEN H. S., KARAKAYA M. A.
3. Uluslararası İlaç ve Eczacılık Kongresi (İVEK), 26 - 29 April 2017
- XXXIV. **Antipsychotic Drugs and the Risk of Sudden Cardiac Death**
DEMİR BÜĞEN M., SÜZEN H. S.
The 2nd International Congress and Workshop of Forensic Toxicology, 26 - 30 May 2016
- XXXV. **The Potential Role of CYP2D6 Pharmacogenetics on Codeine Toxicity**
UÇKUN Z., SÜZEN H. S.
The 2nd International Congress and Workshop of Forensic Toxicology, 26 - 30 May 2016
- XXXVI. **Pharmacogenetics Role in Forensic Toxicology**
SÜZEN H. S.
The 2nd International Congress and Workshop of Forensic Toxicology, 26 - 30 May 2016
- XXXVII. **Determination of Sildenafil in Adulterated Herbal Supplements by HPLC UV**
DURAL E., SÜZEN H. S., SÖYLEMEZOĞLU T.
The 2nd International Congress and Workshop of Forensic Toxicology, 26 - 30 May 2016
- XXXVIII. **Comparisons of Mirtazapine Determination Methods with High Performance Liquid Chromatography**
DURAL E., ÖZCAN H., SÜZEN H. S.
The 2nd International Congress and Workshop of Forensic Toxicology, 26 - 30 May 2016
- XXXIX. **The impact of genetic differences on SSRIs metabolism in depressed patients**
SÜZEN H. S., UÇKUN Z., YUCEARTUN N., BASKAK B., ÖZEL KIZIL E. T., ÖZDEMİR REZAKİ H., ÖZGÜVEN H.
Turk Heltox Toxicology Congress, 21 - 24 October 2015
- XL. **5 HT2A receptor 102T C polymorphism and incidence of nausea induced by sertraline treatment**
DEMİR BÜĞEN M., UÇKUN Z., YÜCE N., BASKAK B., SÜZEN H. S.
Turk Heltox Toxicology Congress, 21 - 24 October 2015
- XLI. **Molecular Analysis of CYP2B6 Gene A785G Polymorphism in a Turkish Population**
SÜZEN H. S., YUCEARTUN N.
3rd ESPT Conference, 7 - 10 October 2015, vol.30
- XLII. **THE ASSOCIATION OF SEROTONINE 2A RECEPTOR 102 T/C POLYMORPHISM AND NAUSEA IN CITALOPRAM TREATED PATIENTS**
DEMİR BÜĞEN M., BASKAK B., Devrimci Özgüven H., Kızıl Özel T., SÜZEN H. S.
11th International Symposium on Pharmaceutical Sciences, 9 - 12 June 2015
- XLIII. **The association of serotonin 2A receptor 102T C polymorphism and nausea in citalopram treated patients**
DEMİR BÜĞEN M., BASKAK B., ÖZEL KIZIL E. T., ÖZGÜVEN H., SÜZEN H. S.
11th International Symposium on Pharmaceutical Sciences, 9 - 12 June 2015

- XLIV. **Correlation between some cytokine gene polymorphisms and susceptibility to type 2 diabetes**
ATEŞ İ., ALTUNER D., SÜZEN H. S., KARAKAYA M. A.
11th International Symposium on Pharmaceutical Sciences, 9 - 12 June 2015
- XLV. **CYP2C19 17 Polymorphism and Major Depression Patients Treated with Citalopram**
UÇKUN Z., BASKAK B., ÖZDEMİR REZAKİ H., ÖZEL KIZIL E. T., ÖZGÜVEN H., SÜZEN H. S.
11th International Symposium on Pharmaceutical Sciences, 9 - 12 June 2015
- XLVI. **The impact of xenobiotic metabolizing enzyme polymorphisms on cytogenetic biomarkers in Turkish coke oven workers exposed to polycyclic aromatic hydrocarbons**
Iscan M., Ada A. O., Demiroglu C., Yilmazer M., SÜZEN H. S., Demirbag A. E., Efe S., Alemdar Y., Burgaz S.
49th Congress of the European-Societies-of-Toxicology (EUROTOX), Interlaken, Switzerland, 1 - 04 September 2013, vol.221
- XLVII. **THE ROLE OF CYP2C19 POLYMORPHISM IN MAJOR DEPRESSION PATIENTS TREATED WITH CITALOPRAM**
Uckun Z., BASKAK B., ÖZEL KIZIL E. T., ÖZGÜVEN H., SÜZEN H. S.
14th Biennial Meeting of the European-Behavioural-Pharmacology-Society, Amsterdam, Netherlands, 26 - 29 August 2011, vol.22
- XLVIII. **The role of CYP1A1 (Ile462Val) and CYP1B1 (Asn453Ser) polymorphisms in response to chemotherapy and survival in lung cancer patients**
ADA A. O., Bilgen S., KUNAK C. S., Hancer F., SÜZEN H. S., Alpar S., Gulhan M., Kurt B., Iscan M.
46th Congress of the European-Societies-of-Toxicology, Dresden, Germany, 13 - 16 September 2009, vol.189
- XLIX. **Influences of genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 on the baseline level of micronuclei in human lymphocytes**
Burgaz S., Ada A., Demiroglu C., Yilmazer-Musa M., SÜZEN H. S., Alemdar Y., Efe S., Iscan M.
10th International Congress of Toxicology, Tampere, Finland, 11 - 15 July 2004, vol.197, pp.254

Supported Projects

SÜZEN H. S., TUBITAK Project, Kanser Hastalarında Kalıcı Organik Kirletici Düzeyleri Maruziyet Genetik Yatkınlık ve Moleküler Hasarın Biyogöstergeleri, 2014 - 2018

SÜZEN H. S., ÖZGÜVEN H., BASKAK B., Project Supported by Higher Education Institutions, MET reseptör tirozin kinaz CC polimorfizmi olan otizm spektrum bozukluklu bireylerde sosyal bilişsel beceriler sırasındaki beyin korteksi hemodinamik yanıtları, 2014 - 2017

SÜZEN H. S., Project Supported by Higher Education Institutions, Sildenafil düzeylerinin pulmoner arteriyel hipertansiyon hasta plazmalarında kromatografik yöntemle belirlenmesi ve bitkisel kökenli ürünlerde illegal varlığının araştırılması, 2013 - 2016

ATEŞ İ., SÜZEN H. S., Project Supported by Higher Education Institutions, Tip 2 Diyabet Hastalığı Komplikasyonlarının Gelişiminde Rol Oynayan Sitokin Gen Polimorfizmlerinin Araştırılması, 2015 - 2015

SÜZEN H. S., Project Supported by Higher Education Institutions, Mirtazapinin İnsan Biyolojik Örneklerinde Yüksek Performanslı Sıvı Kromatografisi YPSK ile Tayini, 2013 - 2015

Memberships / Tasks in Scientific Organizations

Türk Toksikoloji Derneği, Vice President, 2012 - 2014, Turkey

Scientific Refereeing

Project Supported by Higher Education Institutions, BAP Research Project, Kirşehir Ahi Evran University, Turkey, April 2022

Project Supported by Higher Education Institutions, BAP Research Project, Kirşehir Ahi Evran University, Turkey, April 2021
Project Supported by Higher Education Institutions, BAP Research Project, Sivas Cumhuriyet University, Turkey, January 2021
Project Supported by Higher Education Institutions, BAP Research Project, Kirşehir Ahi Evran University, Turkey, September 2020
Project Supported by Higher Education Institutions, BAP Research Project, Sivas Cumhuriyet University, Turkey, May 2020

Scientific Consultations

TÜBİTAK, Other, Ankara University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Turkey, 2022 - 2022

Metrics

Publication: 130
Citation (WoS): 641
Citation (Scopus): 753
H-Index (WoS): 15
H-Index (Scopus): 16

Scholarships

Toksikoloji Doktorası, YOK, 1992 - 1996